Propanc Biopharma Secures $100 Million Financing Agreement with Hexstone Capital
ByAinvest
Wednesday, Oct 15, 2025 8:47 am ET1min read
PPCB--
Propanc Biopharma has entered a strategic financing agreement of up to $100 million with Hexstone Capital. The agreement includes the issuance of Series C Convertible Preferred Stock and Warrants exercisable for up to $99 million. The funding will accelerate the development of Propanc's clinical pipeline and leverage Hexstone's experience in Digital Asset Treasury companies. The goal is to grow the treasury to $100 million within 12 months.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet